Critique: Acting FDA leader tries to explain past Planned Parenthood work to abortion opponents

Source: politico
Authors: Alice Miranda Ollstein, David Lim
URL: https://www.politico.com/news/2026/05/15/new-fda-leader-rushes-to-reassure-anti-abortion-leaders-they-still-have-questions-00923657

What the article reports

Acting FDA Commissioner Kyle Diamantas made a series of calls to prominent anti-abortion leaders this week to explain his prior legal work representing Planned Parenthood at a Florida property-rights case, promising to be "the most pro-life head of FDA we've ever had." Court records show his name appeared on certain Planned Parenthood briefs from 2014 to 2017, while Diamantas and colleagues claim he asked off the case around 2015 on moral grounds. The article also covers the broader context of tension between anti-abortion activists and the FDA over its mifepristone review following former Commissioner Makary's resignation.

Factual accuracy — Adequate

The article grounds specific claims in verifiable sources: court records, named attorneys, and named activists. The 2014–2017 date range for Diamantas' name appearing on briefs is corroborated by citing a specific 2016 oral-argument request. The claim that mifepristone is "used in more than two-thirds of abortions" is presented without a source — this is a frequently cited Guttmacher/KFF-sourced statistic that reporters often state without attribution, but the article offers no citation. The assertion that telehealth availability dates to "2021" is accurate and specific. One tension worth flagging: the article states Diamantas "played an active role in litigating" the case, which is an authorial characterization that the court records partially support (he was co-counsel, he argued against an injunction) but that his former boss disputes as to the depth and duration of that involvement — readers should know this is contested.

Framing — Mostly neutral

1. Headline framing: "tries to explain past Planned Parenthood work" uses "tries" — a verb that implies incomplete success or inadequacy — rather than the more neutral "explains" or "addresses." This subtly colors the reader's expectation before the story begins.

2. Unattributed characterization: "The concerns over the acting FDA leader's record follow a monthslong standoff" — "standoff" is an authorial framing choice, not a quote, that positions the FDA-activist dynamic as adversarial without attribution.

3. Quoted promise foregrounded: Hawkins' reported quote that Diamantas promised to be "the most pro-life head of FDA we've ever had" is placed high in the piece, before the extensive document-based material that complicates the activist reaction, which creates an early impression the piece then partially walks back.

4. Balanced skepticism: The article does give roughly equal weight to critics who are unconvinced and to sources vouching for Diamantas — the Senate aide's "the story isn't adding up" is offset by Litchford's defense and Angell's "accident" speculation, without one side editorially endorsed.

Source balance

Ratio: Voices skeptical or critical of Diamantas outnumber defenders roughly 6:3, with the skeptical side including multiple anonymous sources. Notably absent: any independent legal-ethics voice who could contextualize whether junior-associate representation in a landlord-tenant case is standard or unusual; any reproductive-health advocate or mifepristone-access perspective; any named Senate Republican willing to speak on record.

Omissions

1. Routine legal representation context. The article does not explain that associates at large law firms are routinely assigned clients without choosing them, and that bar rules generally permit this. An independent legal-ethics expert could have addressed whether asking off a case on moral grounds is typical or notable — its absence lets the "he defended Planned Parenthood" framing stand unanswered from an objective standpoint.

2. The Hilary Perkins parallel is noted but underdeveloped. The article mentions Perkins resigned after representing the Biden administration on mifepristone and "said she was personally opposed to abortion and was merely doing her job as a lawyer" — but does not directly draw the parallel to Diamantas' situation, which would give readers a ready comparison case.

3. Mifepristone safety review status. Readers are told there is a review underway and activists want the drug restricted, but the article gives no sense of the scientific or regulatory posture: what the current REMS entails, what prior reviews concluded, or what "completing" a review would mean in practice.

4. Diamantas' other professional background. The anonymous activist notes "he has no other record of work related to abortion" — but the article provides no further biography of Diamantas, leaving readers with almost no context for who he is beyond this one case.

What it does well

• Document-grounded reporting: The piece anchors factual claims in actual court records ("his name still appeared on certain briefs in the state Supreme Court case as late as 2017") rather than relying solely on competing characterizations — a meaningful act of verification.
• Named opposing counsel: Securing Derek Angell on record as opposing counsel — a source with no stake in defending Diamantas — adds credibility. His quote "Derek, I stopped working on this a long time ago" is an unusually direct primary source for an inside-Washington personnel story.
• Presenting activist skepticism in their own words: Rather than summarizing activist discontent, the article quotes specific characterizations ("rearranging deck chairs," "ambiguous about how long he worked on the case") that let readers hear texture and range within the anti-abortion coalition.
• The Oxley quote adds complexity: Including Gavin Oxley's observation that "we also have to look upwards" usefully prevents the piece from reducing the mifepristone story to one official's record.

Rating

Overall: 7/10 — A document-grounded accountability piece that uncovers a real discrepancy in Diamantas' record but relies too heavily on anonymous critics and omits context that would let readers independently evaluate the significance of routine legal representation.